Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 702-708

  Lengruber, Renan B ^a   Delviks Frankenberry, Krista A ^b   Nikolenko, Galina N ^b,d   Baumann, Jessica ^b   Santos, André F ^a   Pathak, Vinay K ^b   Soares, Marcelo A ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d Meso Scale Discovery   (United States)

Author keywords

AZT; NVP; Resistance mutations; TAMs

Indexed keywords

NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; BRAZIL; CARBOXY TERMINAL SEQUENCE; DOSE RESPONSE; DRUG SENSITIVITY; GENE MUTATION; GENE SEQUENCE; HUMAN; MOLECULAR CLONING; PATIENT CODING; PHENOTYPE; SEQUENCE DATABASE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BRAZIL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION, MISSENSE; NEVIRAPINE; PROTEIN STRUCTURE, TERTIARY; THYMIDINE; ZIDOVUDINE;

EID: 79952786073     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr005     Document Type: Article

References (31)

1. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504.
2. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-45.
3. Delviks-Frankenberry KA, Nikolenko GN, Barr R et al. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007; 81: 6837-45.
4. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA 2008; 105: 10943-8.
5. Nikolenko GN, Delviks-Frankenberry KA, Palmer S et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104: 317-22.
6. Nikolenko GN, Palmer S, Maldarelli F et al. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102: 2093-8.
7. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008; 47: 14020-7.
8. Zelina S, Sheen CW, Radzio J et al. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother 2008; 52: 157-63.
9. Kemp SD, Shi C, Bloor S et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998; 72: 5093-8.
10. Yap SH, Sheen CW, Fahey J et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4: e335.
11. Hachiya A, Kodama EN, Sarafianos SG et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82: 3261-70.
12. Brehm JH, Koontz D, Meteer JD et al. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 2007; 81: 7852-9.
13. Radzio J, Yap SH, Tachedjian G et al. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids 2010; 24: 659-67.
14. Sluis-Cremer N, Moore K, Radzio J et al. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Aids 2010; 24: 317-9.
15. Ehteshami M, Beilhartz GL, Scarth BJ et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283: 22222-32.
16. Nikolenko GN, Delviks-Frankenberry KA, Pathak VK. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2010; 84: 5238-49.
17. Figueiredo A, Zelina S, Sluis-Cremer N et al. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr HIV Res 2008; 6: 130-7.
18. Dau B, Ayers D, Singer J et al. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr 2010; 54: 160-6.
19. von Wyl V, Ehteshami M, Demeter LM et al. HIV-1 Reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis 2010; 51: 620-8.
20. Hachiya A, Shimane K, Sarafianos SG et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res 2009; 82: 115-21.
21. Santos AF, Lengruber RB, Soares EA et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008; 3: e1781.
22. Cane PA, Green H, Fearnhill E et al. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. Aids 2007; 21: 447-55.
23. Hu Z, Giguel F, Hatano H et al. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006; 80: 7020-7.
24. Yee JK, Miyanohara A, LaPorte P et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564-8.
25. Delviks-Frankenberry KA, Pathak VK. The 'connection' between HIV drug resistance and RNase H. Viruses 2010; 2: 1476-503.
26. Ntemgwa M, Wainberg MA, Oliveira M et al. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother 2007; 51: 3861-9.
27. Waters JM, O'Neal W, White KL et al. Mutations in the thumbconnection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther 2009; 14: 231-9.
28. Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F et al. Subtype-specific differences in the HIV-1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher AZT resistance. J Virol 2009; 83: 8502-13.
29. Gupta S, Fransen S, Paxinos EE et al. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother 2010; 54: 1973-80.
30. Soares EA, Makamche MF, Siqueira JD et al. Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naive Cameroonian subjects with advanced disease. J Clin Virol 2010; 48: 173-9.
31. Winters B, Van Craenenbroeck E, Van der Borght K et al. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods 2009; 162: 101-8.